Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rocket PharmaceuticalsRCKT +9.28%34 12-1 Month Momentum % is 18.21% as of Aug. 19, 2026. GuruFocus rates RCKT with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,359 Biotechnology companies, Rocket Pharmaceuticals ranks better than 70.86% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-19), Rocket Pharmaceuticals's 12-1 Month Momentum % is 18.21%.
The industry rank for Rocket Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:
RCKT's 12-1 Month Momentum % is ranked better than 70.86% of 1359
companies
in the Biotechnology industry
Industry Median: -19.95
vs RCKT: 18.21
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Rocket Pharmaceuticals 12-1 Month Momentum % Related Terms
RCKT vs UPB, ABEO, INDP: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Rocket Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rocket Pharmaceuticals 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Rocket Pharmaceuticals's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rocket Pharmaceuticals (RCKT) has a 12-1 Month Momentum % of 18.21% as of Aug. 19, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Rocket Pharmaceuticals and its competitors. According to the industry distribution chart, Rocket Pharmaceuticals ranks #396 out of 1359 companies in the Biotechnology industry, placing it in the top 29.1%.
Is Rocket Pharmaceuticals' 12-1 Month Momentum % too high?
Rocket Pharmaceuticals' current 12-1 Month Momentum % is 18.21%. Based on the distribution chart, Rocket Pharmaceuticals ranks #396 out of 1359 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rocket Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' 12-1 Month Momentum % compare to UPB and ABEO?
According to the Biotechnology industry distribution chart, Rocket Pharmaceuticals ranks #396 out of 1359 companies for 12-1 Month Momentum %. This puts Rocket Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Rocket Pharmaceuticals and its competitors. Rocket Pharmaceuticals's current 12-1 Month Momentum % is 18.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current 12-1 Month Momentum % of 18.21%. The current 12-1 Month Momentum % is 18.21%. Rocket Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current 12-1 Month Momentum % is 18.21% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
34GF Score
Get the complete analysis for RCKT
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RCKT has been successfully added to your 
